Compare · CLGN vs ZBH
CLGN vs ZBH
Side-by-side comparison of CollPlant Biotechnologies Ltd (CLGN) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLGN and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $17.61B, about 3340.5x CLGN ($5.3M).
- Over the past year, CLGN is down 79.1% and ZBH is down 3.2% - ZBH leads by 75.9 points.
- ZBH has been more active in the news (11 items in the past 4 weeks vs 4 for CLGN).
- ZBH has more recent analyst coverage (25 ratings vs 1 for CLGN).
- Company
- CollPlant Biotechnologies Ltd
- Zimmer Biomet Holdings Inc.
- Price
- $0.37-13.31%
- $91.06-3.17%
- Market cap
- $5.3M
- $17.61B
- 1M return
- +1.96%
- +4.47%
- 1Y return
- -79.09%
- -3.15%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 4
- 11
- Recent ratings
- 1
- 25
CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants that are used for the regeneration of breast tissue; injectable implants to promote breast tissue regeneration; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. It has a co-development agreement with 3D Systems Corporation for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest CLGN
- SEC Form F-3 filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT
- SEC Form 6-K filed by CollPlant Biotechnologies Ltd
- COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
- New insider Evans Hugh M claimed ownership of 10,000 units of Restricted Share Units and claimed ownership of 340,554 units of Ordinary Shares (SEC Form 3)
- SEC Form EFFECT filed by CollPlant Biotechnologies Ltd
- SEC Form 424B3 filed by CollPlant Biotechnologies Ltd
- Amendment: SEC Form F-1/A filed by CollPlant Biotechnologies Ltd
Latest ZBH
- Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
- Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
- BMO Capital Markets initiated coverage on Zimmer Biomet with a new price target
- SEC Form 4 filed by Director Hilado Maria Teresa
- SEC Form 4 filed by Director Kurdikar Devdatt
- SEC Form 4 filed by Director Hagemann Robert
- SEC Form 4 filed by Director Higgins Arthur J
- SEC Form 4 filed by Director Kolli Sreelakshmi
- SEC Form 4 filed by Director Farrell Michael J.
- SEC Form 4 filed by Director Shapiro Louis